Odisha: IIT Bhubaneswar Signs Agreement for Novel TB Vaccine Technology
Bhubaneswar, November 24, 2025 – In a significant advancement for indigenous tuberculosis (TB) vaccine research, the Indian Institute of Technology (IIT) Bhubaneswar, the Institute of Life Sciences (ILS), and the National Research Development Corporation (NRDC) have entered into a Quadripartite License Agreement with TechInvention Lifecare Limited. This agreement marks a pivotal step towards the technology transfer and potential commercialization of a groundbreaking new vaccine candidate known as the “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”
Importance of the Agreement
The primary objective of this agreement is to facilitate the transition of the vaccine from laboratory research to product development and, ultimately, to commercial deployment. This initiative is crucial as tuberculosis remains one of the most lethal infectious diseases worldwide, claiming approximately 1.23 million lives in 2024 alone, according to the World Health Organization (WHO).
Current Challenges in TB Vaccination
Despite the existence of the Bacillus Calmette Guérin (BCG) vaccine, which was developed over a century ago, the current vaccination strategy is inadequate. The BCG vaccine provides limited protection, primarily to infants, and is largely ineffective in preventing pulmonary TB in adolescents and adults. This gap in effective vaccination highlights a critical unmet need in global health.
Development of the HSP Subunit Vaccine
The next-generation HSP Subunit Vaccine has been developed through collaborative research led by:
- Prof. Ashis Biswas from IIT Bhubaneswar
- Dr. Sunil Kumar Raghav from the Institute of Life Sciences, Bhubaneswar
This innovative vaccine candidate is designed to elicit robust humoral and cell-mediated immune responses, enhancing the protective efficacy of the existing BCG vaccine.
Collaboration and Public Health Potential
The NRDC played a proactive role in identifying and evaluating this promising technology, facilitating the licensing process to ensure its advancement. The collaboration between IIT Bhubaneswar and ILS underscores the strength of India’s research ecosystem and its commitment to addressing pressing public health challenges.
Role of TechInvention Lifecare Limited
As the licensed industry partner, TechInvention Lifecare Limited is expected to play a crucial role in translating this indigenous vaccine technology into a viable public health solution. Their involvement is essential for the successful commercialization of the HSP Subunit Vaccine, which has the potential to significantly impact TB prevention and control efforts.
Global Context of Tuberculosis
Tuberculosis continues to be a major global health issue. The disease is caused by the bacterium Mycobacterium tuberculosis and primarily affects the lungs, although it can also affect other parts of the body. The WHO emphasizes the importance of developing new and effective vaccines to combat TB, especially given the rising rates of drug-resistant strains.
Future Directions
The signing of this agreement is a promising development in the fight against tuberculosis. The HSP Subunit Vaccine has the potential to provide better protection against TB, especially in high-risk populations. The next steps will involve rigorous clinical trials to assess the vaccine’s safety and efficacy before it can be rolled out for public use.
Conclusion
This collaborative effort reflects the dedication of Indian research institutions to innovate and develop solutions for critical health issues. The advancement of the HSP Subunit Vaccine is a testament to the potential of scientific research in addressing global health challenges.
Note: This article is based on information available as of November 2025 and aims to provide an overview of the recent developments in TB vaccine research in India.
